Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1996-11-14
|
| pubmed:abstractText |
Over the past few decades, the life expectancy of patients with sickle cell disease has improved. This has been because of better supportive care and greater awareness of the complications of this disorder. Recent successes of neonatal screening, childhood prophylactic penicillin, and, perhaps, hydroxyurea in adults may further extend the life of sickle cell disease patients. This review will do the following: 1) briefly highlight the major aspects of the conventional treatment of sickle cell disease, 2) address the present use of hydroxyurea in more depth, and 3) succinctly preview what the near-term future of treatment may bring.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0002-9629
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
312
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
166-74
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading | |
| pubmed:year |
1996
|
| pubmed:articleTitle |
Review: sickle cell disease: present and future treatment.
|
| pubmed:affiliation |
VA Medical Center, Jackson, MS 39216, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Review
|